Diagnosis, Screening, and Early Detection of Neuroblastoma

• Neuroblastoma symptoms are often subtle at first and depend heavily on where the tumor has formed, ranging from a painless lump in the abdomen to bone pain if the disease has already spread.
• A confirmed diagnosis combines imaging — CT, MRI, and a specialized MIBG scan — urine testing for catecholamine breakdown products, and, ultimately, a tumor biopsy.
• Testing tumor tissue for MYCN gene amplification helps doctors judge how aggressively the cancer is likely to behave, which directly shapes the treatment plan.
• There is no standard, population-wide screening test for neuroblastoma; past mass urine-screening programs for infants were discontinued after they failed to reduce deaths from the disease.
• Children known to carry an inherited risk — such as an ALK or PHOX2B gene change — may be checked periodically for signs of neuroblastoma, generally until around age 10, a plan best set with a genetics specialist.
• Because outcomes are closely tied to how early the disease is found and treated, prompt evaluation of any persistent or unusual symptom in a child remains one of the most useful steps a parent can take.

Recognizing Early Signs of Neuroblastoma in Children

Neuroblastoma symptoms in children are often subtle and non-specific at first, so the disease is not always easy to catch right away. A lump, an occasional fever, or vague fatigue can look like many ordinary childhood illnesses, which is why careful observation by parents and pediatricians matters.

Common Symptoms by Location

Which symptoms appear largely depends on where the tumor has formed and whether it has already spread:

• Abdomen: The most common site — often a painless lump or swelling, abdominal pain, or a feeling of fullness.
• Chest or neck: Breathing difficulty, a persistent cough, or a visible lump; a tumor pressing on nearby nerves can also cause Horner syndrome, marked by a drooped eyelid, a constricted pupil, and diminished sweating on the same side of the face.
• Bone and bone marrow: If the cancer has spread here, bone pain, limping, fatigue, and paleness from anemia can occur.
• Around the eyes: Dark circles or bruising around the eyes and bulging eyes are recognized signs when the disease involves this area.
• Nervous system: Weakness or paralysis, trouble with balance, or, less often, unusual jerky eye and limb movements sometimes called opsoclonus-myoclonus syndrome.
• Skin (in infants): Small, painless, bluish lumps under the skin.
• General symptoms: Unexplained fever, weight loss, and irritability can accompany more widespread disease.

When to Seek Medical Attention

Any single one of these findings is more often explained by an everyday childhood illness, so it isn’t usually a reason for alarm by itself. What matters is persistence: a lump, pain, or behavior change that doesn’t resolve with typical care, or that is unusual for a particular child, warrants a prompt pediatrician visit — the first step toward a diagnosis if neuroblastoma turns out to be the cause.

The Neuroblastoma Diagnosis Journey

When a child’s symptoms raise concern for neuroblastoma, reaching a definitive diagnosis is a multi-step process that typically involves more than one type of doctor.

Initial Medical Evaluation

The process usually starts with the child’s pediatrician, who takes a detailed history — including how long symptoms have been present and whether there is a family history of cancer — and performs a full physical exam to check for lumps, swelling, or other signs. Depending on what’s found, the pediatrician may order initial tests, such as blood work or an ultrasound, before deciding whether further specialist evaluation is needed.

Referral to Specialists

If these initial findings suggest neuroblastoma is possible, the child is referred onward to a pediatric oncologist — a specialist in childhood cancer care. Pediatric surgeons, radiologists, and pathologists typically join the care team as well, since confirming a neuroblastoma diagnosis and determining how far it has spread both require this kind of coordinated, multidisciplinary evaluation.

Key Diagnostic Methods for Neuroblastoma

Confirming neuroblastoma relies on a combination of imaging studies, laboratory tests, and, ultimately, tissue biopsy. Each plays a distinct role in locating the tumor, gauging how far it has spread, and characterizing how it’s likely to behave.

Imaging Scans and Lab Tests

Several imaging tests help locate the primary tumor and check for spread:

• Ultrasound: Often the first imaging test for an abdominal mass, since it’s quick and noninvasive.
• CT and MRI scans: Provide detailed, cross-sectional images of the tumor’s size, location, and involvement of nearby structures; MRI is particularly useful when a tumor is near the spinal cord.
• MIBG scan: A specialized nuclear medicine scan in which a small amount of a radioactive substance (MIBG) is injected and taken up by neuroblastoma cells, making it especially useful for finding both the primary tumor and any sites of spread throughout the body.
• Chest x-ray or bone x-rays: Can reveal a tumor in the chest or changes in the bones.
• PET scan: Sometimes used if a tumor does not take up MIBG on the scan above.

Alongside imaging, laboratory testing plays a central role. Neuroblastoma cells often release excess catecholamines — hormones involved in the body’s stress response — and two of their breakdown products end up in the urine: homovanillic acid, abbreviated HVA, and vanillylmandelic acid, abbreviated VMA. A 24-hour urine sample showing higher-than-normal VMA or HVA is one of the more distinctive laboratory clues pointing to neuroblastoma. A complete blood count, blood chemistry studies, and a ferritin level are also typically checked, since abnormalities in these can reflect how extensively the disease has spread.

Diagnostic Method	What It Shows
Physical exam and history	Initial assessment of symptoms and overall health
Urine catecholamine studies (VMA/HVA)	Elevated levels are a characteristic laboratory sign of neuroblastoma
CT or MRI scan	Tumor size, location, and extent of local spread
MIBG scan	Detects neuroblastoma at the primary site and at distant sites of spread
Tumor and bone marrow biopsy	Definitive pathological confirmation, including MYCN gene status

Biopsy and Pathological Confirmation

Imaging and lab results can strongly suggest neuroblastoma, but a biopsy — removing a small sample of tumor tissue for examination under a microscope — is what confirms the diagnosis. A pathologist uses this tissue to verify the presence of cancer cells and assess how aggressive they appear. One exception applies to some very young infants: children up to about 6 months old with a small, localized tumor sometimes don’t need an immediate biopsy or surgery, since these tumors can shrink or mature on their own without treatment.

Bone marrow aspiration and biopsy — removing a small sample of marrow, blood, and bone, usually from the hipbone — is also routinely performed to see whether the cancer has reached the bone marrow. Tumor tissue is also checked for MYCN gene amplification — a biomarker test that counts the gene’s copy number within the tumor’s DNA. Having more than 10 copies defines amplification, and MYCN-amplified tumors tend to grow and spread faster, which directly shapes how aggressively the cancer is treated. Testing for changes in the ALK gene is often done alongside this, since ALK changes can also influence the treatment plan.

Screening and Early Detection Approaches

Screening means looking for a disease before symptoms appear, and it only works well when a test finds dangerous disease sooner without also flagging many cases that would never have caused harm — a balance that has proven difficult for neuroblastoma.

Urine Catecholamine Screening

In the past, some mass urine-screening programs tested infants — typically around 6 months of age — for elevated VMA and HVA to catch neuroblastoma before symptoms developed. These were largely discontinued, including in the United States, after research found that screening at 6 months did not reduce the number of children who died from the disease: most tumors it found had a good prognosis on their own, including some that might have regressed without treatment, while true high-risk tumors were often not caught any earlier. According to the National Cancer Institute, neuroblastoma has no established, population-wide screening test, and screening itself is not risk-free — it can lead to overdiagnosis and to inaccurate results that trigger unneeded follow-up testing.

The exception is children already known to carry a higher genetic risk — for example, an inherited ALK or PHOX2B gene change, or a hereditary condition such as Li-Fraumeni or Beckwith-Wiedemann syndrome. These children may be checked periodically for signs of neuroblastoma, generally until around age 10, using an abdominal ultrasound, urine catecholamine testing, and a chest x-ray. How often these checks are needed is a decision to make with the child’s doctor and, ideally, a genetics specialist, based on the specific inherited condition involved.

Role of Routine Check-ups

Outside these high-risk groups, routine pediatric check-ups remain the most consistent way many neuroblastomas are found early. During well-child visits, a pediatrician’s physical exam — feeling the abdomen, tracking growth, and following up on parental concerns — can pick up a mass or other subtle sign that prompts further testing, even without a formal screening protocol behind it. Keeping scheduled visits, and reporting any symptom that doesn’t resolve, is a practical way for parents to support early detection.

The Critical Importance of Early Neuroblastoma Diagnosis

When neuroblastoma is found earlier — often reflected in a younger age at diagnosis and a tumor that hasn’t yet spread widely — treatment can frequently be less intensive, which matters for a child’s later quality of life. How stage and age at diagnosis translate into long-term outcomes is covered on our dedicated survival-rate and prognosis page; broadly, disease found and treated while still localized tends to have a substantially better outlook than disease discovered after it has already spread.

Conversely, a delayed diagnosis often means the cancer has had more time to spread — commonly to the bones, bone marrow, or other organs — by the time it’s found. More advanced disease typically calls for more intensive treatment, which may include high-dose chemotherapy with stem cell rescue, radiation therapy, and immunotherapy, each carrying a greater burden of side effects than treatment for localized disease. Recognizing early signs and pursuing prompt diagnostic evaluation remain among the most concrete steps families and clinicians can take to help improve a child’s outcome.

Frequently Asked Questions

What are the most common initial signs of neuroblastoma?

The earliest signs are often subtle and vary by where the tumor has formed. A painless lump or swelling in the abdomen is the most common initial finding, though a lump in the neck or chest, bone pain, unexplained fever, or persistent fatigue can also be early clues. Because these signs overlap with common childhood illnesses, any that persist or seem unusual for a particular child are worth discussing with a pediatrician.

Why is a biopsy essential for diagnosing neuroblastoma?

Imaging and urine tests can strongly suggest neuroblastoma, but only a biopsy — examining a tumor tissue sample under a microscope — confirms the diagnosis. It also allows testing for MYCN gene amplification and other tumor features that shape how aggressively the cancer is treated, information imaging alone cannot provide.

Are there routine screening tests for neuroblastoma?

No. There is no standard, population-wide screening test for neuroblastoma in infants without symptoms; past mass urine-screening programs were discontinued after they failed to reduce deaths from the disease. The exception is children known to carry an inherited genetic risk, who may be offered periodic checks. For most families, routine pediatric check-ups and prompt evaluation of persistent symptoms remain the main paths to early detection.

Sources

• National Cancer Institute – Neuroblastoma Treatment (PDQ®)–Patient Version
• National Cancer Institute – Neuroblastoma Screening (PDQ®)–Patient Version
• MedlinePlus – Neuroblastoma